Deacetylation by SIRT1 Reprograms Inflammation and Cancer

Genes and Cancer

Volumn 4, Issue 3-4, 2013, Pages 135-147

  Liu, Tie Fu ^a   McCall, Charles E ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

cancer; chromatin regulation; inflammation; NF B; SIRT1

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; REACTIVE OXYGEN METABOLITE; REGULATOR PROTEIN; SIRTUIN 1; SUPEROXIDE DISMUTASE; SYNAPTOTAGMIN I; TOLL LIKE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

AMINO TERMINAL SEQUENCE; ARTICLE; AUTOPHAGY; CANCER GROWTH; CARBOXY TERMINAL SEQUENCE; CATALYSIS; CHROMATIN; CHROMATIN STRUCTURE; CHRONIC INFLAMMATION; CYTOLOGY; DEACETYLATION; DNA REPAIR; ENZYME ACTIVATION; ENZYME ACTIVITY; EUCHROMATIN; GENE EXPRESSION; GENE SEQUENCE; GENE SWITCHING; HETEROCHROMATIN; HOMEOSTASIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; INTRACELLULAR SIGNALING; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; NUCLEAR REPROGRAMMING; NUCLEOSOME; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN STRUCTURE;

EID: 84887468471     PISSN: 19476019     EISSN: 19476027     Source Type: Journal    
DOI: 10.1177/1947601913476948     Document Type: Article

References (179)

1. Kuo MH,Allis CD.Roles of histone acetyltransferases and deacetylases in gene regulation.Bioessays. 1998;20:615-26.
2. Hong L,Schroth GP,Matthews HR,Yau P,Bradbury EM.Studies of the DNA binding properties of histone H4 amino terminus: thermal denaturation studies reveal that acetylation markedly reduces the binding constant of the H4 "tail" to DNA.J Biol Chem. 1993;268:305-14.
3. Glozak MA,Sengupta N,Zhang X,Seto E.Acetylation and deacetylation of non-histone proteins.Gene. 2005;363:15-23.
4. Liu TF,Vachharajani VT,Yoza BK,McCall CE.NAD+-dependent sirtuin 1 and 6 proteins coordinate a switch from glucose to fatty acid oxidation during the acute inflammatory response.J Biol Chem. 2012;287:25758-69.
5. Michalek RD,Gerriets VA,Jacobs SR,et al.Cutting edge: distinct glycolytic and lipid oxidative metabolic programs are essential for effector and regulatory CD4+ T cell subsets.J Immunol. 2011;186:3299-303.
6. Kramer OH,Knauer SK,Greiner G,et al.A phosphorylation-acetylation switch regulates STAT1 signaling.Genes Dev. 2009;23:223-35.
7. Basile V,Mantovani R,Imbriano C.DNA damage promotes histone deacetylase 4 nuclear localization and repression of G2/M promoters, via p53 C-terminal lysines.J Biol Chem. 2006;281:2347-57.
8. Vaquero A.The conserved role of sirtuins in chromatin regulation.Int J Dev Biol. 2009;53:303-22.
9. Imai S,Armstrong CM,Kaeberlein M,Guarente L.Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase.Nature. 2000;403:795-800.
10. Li X,Kazgan N.Mammalian sirtuins and energy metabolism.Int J Biol Sci. 2011;7:575-87.
11. Rahman S,Islam R.Mammalian Sirt1: insights on its biological functions.Cell Commun Signal. 2011;9:11.
12. Zhang T,Kraus WL.SIRT1-dependent regulation of chromatin and transcription: linking NAD(+) metabolism and signaling to the control of cellular functions.Biochim Biophys Acta. 2010;1804:1666-75.
13. Calle EE,Rodriguez C,Walker-Thurmond K,Thun MJ.Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults.N Engl J Med. 2003;348:1625-38.
14. Parkin DM.The global health burden of infection-associated cancers in the year 2002.Int J Cancer. 2006;118:3030-44.
15. Zur HH.The search for infectious causes of human cancers: where and why.Virology. 2009;392:1-10.
16. Fukuda K,Kobayashi A,Watabe K.The role of tumor-associated macrophage in tumor progression.Front Biosci (Schol Ed). 2012;4:787-98.
17. Mantovani A,Allavena P,Sica A,Balkwill F.Cancer-related inflammation.Nature. 2008;454:436-44.
18. Bunt SK,Yang L,Sinha P,Clements VK,Leips J,Ostrand-Rosenberg S.Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression.Cancer Res. 2007;67:10019-26.
19. Ostrand-Rosenberg S,Sinha P,Beury DW,Clements VK.Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression.Semin Cancer Biol. 2012;22:275-81.
20. Yasuoka H,Tsujimoto M,Yoshidome K,et al.Cytoplasmic CXCR4 expression in breast cancer: induction by nitric oxide and correlation with lymph node metastasis and poor prognosis.BMC Cancer. 2008;8:340.
21. Shanmugam MK,Sethi G.Role of epigenetics in inflammation-associated diseases.Subcell Biochem. 2012;61:627-57.
22. Yang XJ.The diverse superfamily of lysine acetyltransferases and their roles in leukemia and other diseases.Nucleic Acids Res. 2004;32:959-76.
23. Deng CX.SIRT1, is it a tumor promoter or tumor suppressor?.Int J Biol Sci. 2009;5:147-52.
24. Hursting SD,Berger NA.Energy balance, host-related factors, and cancer progression.J Clin Oncol. 2010;28:4058-65.
25. Kim EJ,Um SJ.SIRT1: roles in aging and cancer.BMB Rep. 2008;41:751-6.
26. Autiero I,Costantini S,Colonna G.Human Sirt-1: molecular modeling and structure-function relationships of an unordered protein.PLoS One. 2009;4:e7350.
27. Pan M,Yuan H,Brent M,Ding EC,Marmorstein R.SIRT1 contains N- and C-terminal regions that potentiate deacetylase activity.J Biol Chem. 2012;287:2468-76.
28. Kang H,Suh JY,Jung YS,Jung JW,Kim MK,Chung JH.Peptide switch is essential for Sirt1 deacetylase activity.Mol Cell. 2011;44:203-13.
29. Tanno M,Sakamoto J,Miura T,Shimamoto K,Horio Y.Nucleocytoplasmic shuttling of the NAD+-dependent histone deacetylase SIRT1.J Biol Chem. 2007;282:6823-32.
30. Sharma A,Gautam V,Costantini S,Paladino A,Colonna G.Interactomic and pharmacological insights on human Sirt-1.Front Pharmacol. 2012;3:40.
31. Borra MT,Langer MR,Slama JT,Denu JM.Substrate specificity and kinetic mechanism of the Sir2 family of NAD+-dependent histone/protein deacetylases.Biochemistry. 2004;43:9877-87.
32. Moazed D.Enzymatic activities of Sir2 and chromatin silencing.Curr Opin Cell Biol. 2001;13:232-8.
33. Huhtiniemi T,Wittekindt C,Laitinen T,et al.Comparative and pharmacophore model for deacetylase SIRT1.J Comput Aided Mol Des. 2006;20:589-99.
34. Kim JE,Chen J,Lou Z.DBC1 is a negative regulator of SIRT1.Nature. 2008;451:583-6.
35. Howitz KT,Bitterman KJ,Cohen HY,et al.Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan.Nature. 2003;425:191-6.
36. Kim EJ,Kho JH,Kang MR,Um SJ.Active regulator of SIRT1 cooperates with SIRT1 and facilitates suppression of p53 activity.Mol Cell. 2007;28:277-90.
37. Stunkel W,Campbell RM.Sirtuin 1 (SIRT1): the misunderstood HDAC.J Biomol Screen. 2011;16:1153-69.
38. Vaquero A,Scher M,Lee D,Erdjument-Bromage H,Tempst P,Reinberg D.Human SirT1 interacts with histone H1 and promotes formation of facultative heterochromatin.Mol Cell. 2004;16:93-105.
39. Fang Y,Nicholl MB.Sirtuin 1 in malignant transformation: friend or foe?.Cancer Lett. 2011;306:10-4.
40. Liu TF,Yoza BK,El GM,Vachharajani VT,McCall CE.NAD+-dependent SIRT1 deacetylase participates in epigenetic reprogramming during endotoxin tolerance.J Biol Chem. 2011;286:9856-64.
41. Hallows WC,Lee S,Denu JM.Sirtuins deacetylate and activate mammalian acetyl-CoA synthetases.Proc Natl Acad Sci U S A. 2006;103:10230-5.
42. Hirschey MD,Shimazu T,Capra JA,Pollard KS,Verdin E.SIRT1 and SIRT3 deacetylate homologous substrates: AceCS1,2 and HMGCS1,2.Aging (Albany NY). 2011;3:635-42.
43. Luo J,Nikolaev AY,Imai S,et al.Negative control of p53 by Sir2alpha promotes cell survival under stress.Cell. 2001;107:137-48.
44. Vaziri H,Dessain SK,Ng EE,et al.hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.Cell. 2001;107:149-59.
45. Schmidt MT,Smith BC,Jackson MD,Denu JM.Coenzyme specificity of Sir2 protein deacetylases: implications for physiological regulation.J Biol Chem. 2004;279:40122-9.
46. Revollo JR,Grimm AA,Imai S.The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells.J Biol Chem. 2004;279:50754-63.
47. Wang T,Zhang X,Bheda P,Revollo JR,Imai S,Wolberger C.Structure of Nampt/PBEF/visfatin, a mammalian NAD+ biosynthetic enzyme.Nat Struct Mol Biol. 2006;13:661-2.
48. Zhang T,Berrocal JG,Frizzell KM,et al.Enzymes in the NAD+ salvage pathway regulate SIRT1 activity at target gene promoters.J Biol Chem. 2009;284:20408-17.
49. Braidy N,Guillemin GJ,Grant R.Effects of kynurenine pathway inhibition on NAD metabolism and cell viability in human primary astrocytes and neurons.Int J Tryptophan Res. 2011;4:29-37.
50. Cohen HY,Miller C,Bitterman KJ,et al.Calorie restriction promotes mammalian cell survival by inducing the SIRT1 deacetylase.Science. 2004;305:390-2.
51. Rodgers JT,Lerin C,Haas W,Gygi SP,Spiegelman BM,Puigserver P.Nutrient control of glucose homeostasis through a complex of PGC-1alpha and SIRT1.Nature. 2005;434:113-8.
52. Tseng RC,Lee CC,Hsu HS,Tzao C,Wang YC.Distinct HIC1-SIRT1-p53 loop deregulation in lung squamous carcinoma and adenocarcinoma patients.Neoplasia. 2009;11:763-70.
53. Wang C,Chen L,Hou X,et al.Interactions between E2F1 and SirT1 regulate apoptotic response to DNA damage.Nat Cell Biol. 2006;8:1025-31.
54. Abdelmohsen K,Pullmann R,Lal A,et al.Phosphorylation of HuR by Chk2 regulates SIRT1 expression.Mol Cell. 2007;25:543-57.
55. Yamakuchi M.MicroRNA regulation of SIRT1.Front Physiol. 2012;3:68.
56. Ford J,Ahmed S,Allison S,Jiang M,Milner J.JNK2-dependent regulation of SIRT1 protein stability.Cell Cycle. 2008;7:3091-7.
57. Dalpke A,Heeg K.Signal integration following Toll-like receptor triggering.Crit Rev Immunol. 2002;22:217-50.
58. McCall CE,Yoza B,Liu T,El GM.Gene-specific epigenetic regulation in serious infections with systemic inflammation.J Innate Immun. 2010;2:395-405.
59. Brown J,Wang H,Hajishengallis GN,Martin M.TLR-signaling networks: an integration of adaptor molecules, kinases, and cross-talk.J Dent Res. 2011;90:417-27.
60. Buerki C,Rothgiesser KM,Valovka T,et al.Functional relevance of novel p300-mediated lysine 314 and 315 acetylation of RelA/p65.Nucleic Acids Res. 2008;36:1665-80.
61. Chen LF,Mu Y,Greene WC.Acetylation of RelA at discrete sites regulates distinct nuclear functions of NF-kappaB.EMBO J. 2002;21:6539-48.
62. Nagorsen D,Deola S,Smith K,et al.Polarized monocyte response to cytokine stimulation.Genome Biol. 2005;6:R15.
63. Ozato K,Tsujimura H,Tamura T.Toll-like receptor signaling and regulation of cytokine gene expression in the immune system.Biotechniques. 2002;:66 70 72-8.
64. Liu TF,Brown CM,El GM,et al.Fueling the flame: bioenergy couples metabolism and inflammation.J Leukoc Biol. 2012;92:499-507.
65. Bouras T,Fu M,Sauve AA,et al.SIRT1 deacetylation and repression of p300 involves lysine residues 1020/1024 within the cell cycle regulatory domain 1.J Biol Chem. 2005;280:10264-76.
66. El GM,Yoza BK,Chen X,Hu J,Hawkins GA,McCall CE.G9a and HP1 couple histone and DNA methylation to TNFalpha transcription silencing during endotoxin tolerance.J Biol Chem. 2008;283:32198-208.
67. He S,Bauman D,Davis JS.Facile synthesis of site-specifically acetylated and methylated histone proteins: reagents for evaluation of the histone code hypothesis.Proc Natl Acad Sci U S A. 2003;100:12033-8.
68. Vaquero A,Scher M,Erdjument-Bromage H,Tempst P,Serrano L,Reinberg D.SIRT1 regulates the histone methyl-transferase SUV39H1 during heterochromatin formation.Nature. 2007;450:440-4.
69. Yoza BK,Hu JY,Cousart SL,Forrest LM,McCall CE.Induction of RelB participates in endotoxin tolerance.J Immunol. 2006;177:4080-5.
70. Schug TT,Xu Q,Gao H,et al.Myeloid deletion of SIRT1 induces inflammatory signaling in response to environmental stress.Mol Cell Biol. 2010;30:4712-21.
71. Yang Z,Kahn BB,Shi H,Xue BZ.Macrophage alpha1 AMP-activated protein kinase (alpha1AMPK) antagonizes fatty acid-induced inflammation through SIRT1.J Biol Chem. 2010;285:19051-9.
72. Fan W,Morinaga H,Kim JJ,et al.FoxO1 regulates Tlr4 inflammatory pathway signalling in macrophages.EMBO J. 2010;29:4223-36.
73. Brunet A,Sweeney LB,Sturgill JF,et al.Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase.Science. 2004;303:2011-5.
74. Daitoku H,Hatta M,Matsuzaki H,et al.Silent information regulator 2 potentiates Foxo1-mediated transcription through its deacetylase activity.Proc Natl Acad Sci U S A. 2004;101:10042-7.
75. Frede S,Stockmann C,Winning S,Freitag P,Fandrey J.Hypoxia-inducible factor (HIF) 1alpha accumulation and HIF target gene expression are impaired after induction of endotoxin tolerance.J Immunol. 2009;182:6470-6.
76. Peyssonnaux C,Cejudo-Martin P,Doedens A,Zinkernagel AS,Johnson RS,Nizet V.Cutting edge: essential role of hypoxia inducible factor-1alpha in development of lipopolysaccharide-induced sepsis.J Immunol. 2007;178:7516-9.
77. Lim JH,Lee YM,Chun YS,Chen J,Kim JE,Park JW.Sirtuin 1 modulates cellular responses to hypoxia by deacetylating hypoxia-inducible factor 1alpha.Mol Cell. 2010;38:864-78.
78. Bordone L,Motta MC,Picard F,et al.Sirt1 regulates insulin secretion by repressing UCP2 in pancreatic beta cells.PLoS Biol. 2006;4:e31.
79. Nishi K,Oda T,Takabuchi S,et al.LPS induces hypoxia-inducible factor 1 activation in macrophage-differentiated cells in a reactive oxygen species-dependent manner.Antioxid Redox Signal. 2008;10:983-95.
80. Levine B,Mizushima N,Virgin HW.Autophagy in immunity and inflammation.Nature. 2011;469:323-35.
81. Saitoh T,Fujita N,Jang MH,et al.Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production.Nature. 2008;456:264-8.
82. Zhou R,Yazdi AS,Menu P,Tschopp J.A role for mitochondria in NLRP3 inflammasome activation.Nature. 2011;469:221-5.
83. Delgado MA,Elmaoued RA,Davis AS,Kyei G,Deretic V.Toll-like receptors control autophagy.EMBO J. 2008;27:1110-21.
84. Jang SY,Kang HT,Hwang ES.Nicotinamide-induced mitophagy: event mediated by high NAD+/NADH ratio and SIRT1 protein activation.J Biol Chem. 2012;287:19304-14.
85. Lee IH,Cao L,Mostoslavsky R,et al.A role for the NAD-dependent deacetylase Sirt1 in the regulation of autophagy.Proc Natl Acad Sci U S A. 2008;105:3374-9.
86. Powell MJ,Casimiro MC,Cordon-Cardo C,et al.Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation.Cancer Res. 2011;71:964-75.
87. Krawczyk CM,Holowka T,Sun J,et al.Toll-like receptor-induced changes in glycolytic metabolism regulate dendritic cell activation.Blood. 2010;115:4742-9.
88. Lawrence T,Gilroy DW.Chronic inflammation: a failure of resolution?.Int J Exp Pathol. 2007;88:85-94.
89. Lawrence T.The nuclear factor NF-kappaB pathway in inflammation.Cold Spring Harb Perspect Biol. 2009;1:a001651.
90. Rajendrasozhan S,Yang SR,Kinnula VL,Rahman I.SIRT1, an antiinflammatory and antiaging protein, is decreased in lungs of patients with chronic obstructive pulmonary disease.Am J Respir Crit Care Med. 2008;177:861-70.
91. Costa CS,Hammes TO,Rohden F,et al.SIRT1 transcription is decreased in visceral adipose tissue of morbidly obese patients with severe hepatic steatosis.Obes Surg. 2010;20:633-9.
92. Clark SJ,Falchi M,Olsson B,et al.Association of sirtuin 1 (SIRT1) gene SNPs and transcript expression levels with severe obesity.Obesity (Silver Spring). 2012;20:178-85.
93. Gorenne I,Kumar S,Gray K,et al.Vascular smooth muscle cell sirtuin 1 protects against DNA damage and inhibits atherosclerosis.Circulation. 2012;:7.
94. Gillum MP,Kotas ME,Erion DM,et al.SirT1 regulates adipose tissue inflammation.Diabetes. 2011;60:3235-45.
95. Massudi H,Grant R,Braidy N,Guest J,Farnsworth B,Guillemin GJ.Age-associated changes in oxidative stress and NAD+ metabolism in human tissue.PLoS One. 2012;7:e42357.
96. Yang SR,Wright J,Bauter M,Seweryniak K,Kode A,Rahman I.Sirtuin regulates cigarette smoke-induced proinflammatory mediator release via RelA/p65 NF-kappaB in macrophages in vitro and in rat lungs in vivo: implications for chronic inflammation and aging.Am J Physiol Lung Cell Mol Physiol. 2007;292:L567-76.
97. Narkiewicz K.Diagnosis and management of hypertension in obesity.Obes Rev. 2006;7:155-62.
98. Boyd GS,Koenigsberg J,Falkner B,Gidding S,Hassink S.Effect of obesity and high blood pressure on plasma lipid levels in children and adolescents.Pediatrics. 2005;116:442-6.
99. Eckel RH,Kahn SE,Ferrannini E,et al.Obesity and type 2 diabetes: what can be unified and what needs to be individualized?.J Clin Endocrinol Metab. 2011;96:1654-63.
100. Calle EE,Kaaks R.Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms.Nat Rev Cancer. 2004;4:579-91.
101. Picard F,Kurtev M,Chung N,et al.Sirt1 promotes fat mobilization in white adipocytes by repressing PPAR-gamma.Nature. 2004;429:771-6.
102. Chalkiadaki A,Guarente L.High-fat diet triggers inflammation-induced cleavage of SIRT1 in adipose tissue to promote metabolic dysfunction.Cell Metab. 2012;16:180-8.
103. Palacios JA,Herranz D,De Bonis ML,Velasco S,Serrano M,Blasco MA.SIRT1 contributes to telomere maintenance and augments global homologous recombination.J Cell Biol. 2010;191:1299-313.
104. Motta MC,Divecha N,Lemieux M,et al.Mammalian SIRT1 represses forkhead transcription factors.Cell. 2004;116:551-63.
105. Hsu CP,Odewale I,Alcendor RR,Sadoshima J.Sirt1 protects the heart from aging and stress.Biol Chem. 2008;389:221-31.
106. Takeda-Watanabe A,Kitada M,Kanasaki K,Koya D.SIRT1 inactivation induces inflammation through the dysregulation of autophagy in human THP-1 cells.Biochem Biophys Res Commun. 2012;427:191-6.
107. Rogge MM.The role of impaired mitochondrial lipid oxidation in obesity.Biol Res Nurs. 2009;10:356-73.
108. Figueiredo PA,Ferreira RM,Appell HJ,Duarte JA.Age-induced morphological, biochemical, and functional alterations in isolated mitochondria from murine skeletal muscle.J Gerontol A Biol Sci Med Sci. 2008;63:350-9.
109. Ramsey KM,Mills KF,Satoh A,Imai S.Age-associated loss of Sirt1-mediated enhancement of glucose-stimulated insulin secretion in beta cell-specific Sirt1-overexpressing (BESTO) mice.Aging Cell. 2008;7:78-88.
110. Quintas A,de Solis AJ,Diez-Guerra FJ,Carrascosa JM,Bogonez E.Age-associated decrease of SIRT1 expression in rat hippocampus: prevention by late onset caloric restriction.Exp Gerontol. 2012;47:198-201.
111. Sack MN,Finkel T.Mitochondrial metabolism, sirtuins, and aging.Cold Spring Harb Perspect Biol. 2012;4:a013102.
112. Nogueiras R,Habegger KM,Chaudhary N,et al.Sirtuin 1 and sirtuin 3: physiological modulators of metabolism.Physiol Rev. 2012;92:1479-514.
113. Hirschey MD,Shimazu T,Goetzman E,et al.SIRT3 regulates mitochondrial fatty-acid oxidation by reversible enzyme deacetylation.Nature. 2010;464:121-5.
114. Hirschey MD,Shimazu T,Jing E,et al.SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome.Mol Cell. 2011;44:177-90.
115. Finley LW,Carracedo A,Lee J,et al.SIRT3 opposes reprogramming of cancer cell metabolism through HIF1alpha destabilization.Cancer Cell. 2011;19:416-28.
116. Singer M,Brealey D.Mitochondrial dysfunction in sepsis.Biochem Soc Symp. 1999;66:149-66.
117. Qiao L,Shao J.SIRT1 regulates adiponectin gene expression through Foxo1-C/enhancer-binding protein alpha transcriptional complex.J Biol Chem. 2006;281:39915-24.
118. Maitra U,Gan L,Chang S,Li L.Low-dose endotoxin induces inflammation by selectively removing nuclear receptors and activating CCAAT/enhancer-binding protein delta.J Immunol. 2011;186:4467-73.
119. Maitra U,Deng H,Glaros T,et al.Molecular mechanisms responsible for the selective and low-grade induction of proinflammatory mediators in murine macrophages by lipopolysaccharide.J Immunol. 2012;189:1014-23.
120. Zhang Z,Lowry SF,Guarente L,Haimovich B.Roles of SIRT1 in the acute and restorative phases following induction of inflammation.J Biol Chem. 2010;285:41391-401.
121. Coussens LM,Werb Z.Inflammation and cancer.Nature. 2002;420:860-7.
122. Galdiero MR,Garlanda C,Jaillon S,Marone G,Mantovani A.Tumor associated macrophages and neutrophils in tumor progression.J Cell Physiol. 2012;:.
123. Richards ME,Rickert RR,Nance FC.Crohn's disease-associated carcinoma: a poorly recognized complication of inflammatory bowel disease.Ann Surg. 1989;209:764-73.
124. Lavery IC,Chiulli RA,Jagelman DG,Fazio VW,Weakley FL.Survival with carcinoma arising in mucosal ulcerative colitis.Ann Surg. 1982;195:508-12.
125. Raimondi S,Lowenfels AB,Morselli-Labate AM,Maisonneuve P,Pezzilli R.Pancreatic cancer in chronic pancreatitis: aetiology, incidence, and early detection.Best Pract Res Clin Gastroenterol. 2010;24:349-58.
126. Brenner DR,Boffetta P,Duell EJ,et al.Previous lung diseases and lung cancer risk: a pooled analysis from the International Lung Cancer Consortium.Am J Epidemiol. 2012;176:573-85.
127. Compare D,Rocco A,Nardone G.Risk factors in gastric cancer.Eur Rev Med Pharmacol Sci. 2010;14:302-8.
128. El-Serag HB.Epidemiology of viral hepatitis and hepatocellular carcinoma.Gastroenterology. 2012;142:1264-73.
129. Rayburn ER,Ezell SJ,Zhang R.Anti-inflammatory agents for cancer therapy.Mol Cell Pharmacol. 2009;1:29-43.
130. Zerbini LF,Tamura RE,Correa RG,et al.Combinatorial effect of non-steroidal anti-inflammatory drugs and NF-kappaB inhibitors in ovarian cancer therapy.PLoS One. 2011;6:e24285.
131. Serraino D,Piselli P,Busnach G,et al.Risk of cancer following immunosuppression in organ transplant recipients and in HIV-positive individuals in southern Europe.Eur J Cancer. 2007;43:2117-23.
132. Pikarsky E,Porat RM,Stein I,Abramovitch R,et al.NF-kappaB functions as a tumour promoter in inflammation-associated cancer.Nature. 2004;431:461-6.
133. Qin B,Cheng K.Silencing of the IKKepsilon gene by siRNA inhibits invasiveness and growth of breast cancer cells.Breast Cancer Res. 2010;12:R74.
134. Waris G,Ahsan H.Reactive oxygen species: role in the development of cancer and various chronic conditions.J Carcinog. 2006;5:14.
135. Devasagayam TP,Tilak JC,Boloor KK,Sane KS,Ghaskadbi SS,Lele RD.Free radicals and antioxidants in human health: current status and future prospects.J Assoc Physicians India. 2004;52:794-804.
136. Vafa O,Wade M,Kern S,et al.c-Myc can induce DNA damage, increase reactive oxygen species, and mitigate p53 function: a mechanism for oncogene-induced genetic instability.Mol Cell. 2002;9:1031-44.
137. Kobayashi Y,Qi X,Chen G.MK2 regulates Ras oncogenesis through stimulating ROS production.Genes Cancer. 2012;3:521-30.
138. Van RH,Ikeno Y,Hamilton M,et al.Life-long reduction in MnSOD activity results in increased DNA damage and higher incidence of cancer but does not accelerate aging.Physiol Genomics. 2003;16:29-37.
139. Ma X,Becker Buscaglia LE,Barker JR,Li Y.MicroRNAs in NF-kappaB signaling.J Mol Cell Biol. 2011;3:159-66.
140. Tsitsiou E,Lindsay MA.microRNAs and the immune response.Curr Opin Pharmacol. 2009;9:514-20.
141. Nahid MA,Satoh M,Chan EK.Mechanistic role of microRNA-146a in endotoxin-induced differential cross-regulation of TLR signaling.J Immunol. 2011;186:1723-34.
142. Tili E,Michaille JJ,Wernicke D,et al.Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer.Proc Natl Acad Sci U S A. 2011;108:4908-13.
143. Sandhu SK,Volinia S,Costinean S,et al.miR-155 targets histone deacetylase 4 (HDAC4) and impairs transcriptional activity of B-cell lymphoma 6 (BCL6) in the Emu-miR-155 transgenic mouse model.Proc Natl Acad Sci U S A. 2012;109:20047-52.
144. Costinean S,Zanesi N,Pekarsky Y,et al.Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice.Proc Natl Acad Sci U S A. 2006;103:7024-9.
145. Suh SS,Yoo JY,Nuovo GJ,et al.MicroRNAs/TP53 feedback circuitry in glioblastoma multiforme.Proc Natl Acad Sci U S A. 2012;109:5316-21.
146. Hanahan D,Weinberg RA.The hallmarks of cancer.Cell. 2000;100:57-70.
147. Colotta F,Allavena P,Sica A,Garlanda C,Mantovani A.Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability.Carcinogenesis. 2009;30:1073-81.
148. Xu Y,Josson S,Fang F,et al.RelB enhances prostate cancer growth: implications for the role of the nuclear factor-kappaB alternative pathway in tumorigenicity.Cancer Res. 2009;69:3267-71.
149. Huffman DM,Grizzle WE,Bamman MM,et al.SIRT1 is significantly elevated in mouse and human prostate cancer.Cancer Res. 2007;67:6612-8.
150. Kozako T,Aikawa A,Shoji T,et al.High expression of the longevity gene product SIRT1 and apoptosis induction by sirtinol in adult T-cell leukemia cells.Int J Cancer. 2012;131:2044-55.
151. Stunkel W,Peh BK,Tan YC,et al.Function of the SIRT1 protein deacetylase in cancer.Biotechnol J. 2007;2:1360-8.
152. Hida Y,Kubo Y,Murao K,Arase S.Strong expression of a longevity-related protein, SIRT1, in Bowen's disease.Arch Dermatol Res. 2007;299:103-6.
153. Vaziri H,Dessain SK,Ng EE,et al.hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.Cell. 2001;107:149-59.
154. Luo J,Nikolaev AY,Imai S,et al.Negative control of p53 by Sir2alpha promotes cell survival under stress.Cell. 2001;107:137-48.
155. Liu T,Liu PY,Marshall GM.The critical role of the class III histone deacetylase SIRT1 in cancer.Cancer Res. 2009;69:1702-5.
156. Fraga MF,Ballestar E,Villar-Garea A,et al.Loss of acetylation at Lys16 and trimethylation at Lys20 of histone H4 is a common hallmark of human cancer.Nat Genet. 2005;37:391-400.
157. Wang RH,Sengupta K,Li C,et al.Impaired DNA damage response, genome instability, and tumorigenesis in SIRT1 mutant mice.Cancer Cell. 2008;14:312-23.
158. Bosch-Presegue L,Raurell-Vila H,Marazuela-Duque A,et al.Stabilization of Suv39H1 by SirT1 is part of oxidative stress response and ensures genome protection.Mol Cell. 2011;42:210-23.
159. Li Z,Chen L,Kabra N,Wang C,Fang J,Chen J.Inhibition of SUV39H1 methyltransferase activity by DBC1.J Biol Chem. 2009;284:10361-6.
160. Pruitt K,Zinn RL,Ohm JE,et al.Inhibition of SIRT1 reactivates silenced cancer genes without loss of promoter DNA hypermethylation.PLoS Genet. 2006;2:e40.
161. Oberdoerffer P,Michan S,McVay M,et al.SIRT1 redistribution on chromatin promotes genomic stability but alters gene expression during aging.Cell. 2008;135:907-18.
162. Banks AS,Kon N,Knight C,et al.SirT1 gain of function increases energy efficiency and prevents diabetes in mice.Cell Metab. 2008;8:333-41.
163. Pfluger PT,Herranz D,Velasco-Miguel S,Serrano M,Tschop MH.Sirt1 protects against high-fat diet-induced metabolic damage.Proc Natl Acad Sci U S A. 2008;105:9793-8.
164. Liang XJ,Finkel T,Shen DW,Yin JJ,Aszalos A,Gottesman MM.SIRT1 contributes in part to cisplatin resistance in cancer cells by altering mitochondrial metabolism.Mol Cancer Res. 2008;6:1499-506.
165. Kojima K,Ohhashi R,Fujita Y,et al.A role for SIRT1 in cell growth and chemoresistance in prostate cancer PC3 and DU145 cells.Biochem Biophys Res Commun. 2008;373:423-8.
166. Ghaffari S.Cancer, stem cells and cancer stem cells: old ideas, new developments.F1000 Med Rep. 2011;3:23.
167. Li L,Wang L,Li L,et al.Activation of p53 by SIRT1 inhibition enhances elimination of CML leukemia stem cells in combination with imatinib.Cancer Cell. 2012;21:266-81.
168. Petrucelli N,Daly MB,Feldman GL.Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med. 2010;12:245-59.:.
169. Wang RH,Zheng Y,Kim HS,et al.Interplay among BRCA1, SIRT1, and Survivin during BRCA1-associated tumorigenesis.Mol Cell. 2008;32:11-20.
170. Tanaka K,Iwamoto S,Gon G,Nohara T,Iwamoto M,Tanigawa N.Expression of survivin and its relationship to loss of apoptosis in breast carcinomas.Clin Cancer Res. 2000;6:127-34.
171. Satoh K,Kaneko K,Hirota M,Masamune A,Satoh A,Shimosegawa T.Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors.Cancer. 2001;92:271-8.
172. Kawasaki H,Toyoda M,Shinohara H,et al.Expression of survivin correlates with apoptosis, proliferation, and angiogenesis during human colorectal tumorigenesis.Cancer. 2001;91:2026-32.
173. Jin Z,Tamura G,Tsuchiya T,et al.Adenomatous polyposis coli (APC) gene promoter hypermethylation in primary breast cancers.Br J Cancer. 2001;85:69-73.
174. Firestein R,Blander G,Michan S,et al.The SIRT1 deacetylase suppresses intestinal tumorigenesis and colon cancer growth.PLoS One. 2008;3:e2020.
175. Lee CM,Shvartsman H,Deavers MT,et al.Beta-catenin nuclear localization is associated with grade in ovarian serous carcinoma.Gynecol Oncol. 2003;88:363-8.
176. Arozarena I,Bischof H,Gilby D,Belloni B,Dummer R,Wellbrock C.In melanoma, beta-catenin is a suppressor of invasion.Oncogene. 2011;30:4531-43.
177. Powell MJ,Casimiro MC,Cordon-Cardo C,et al.Disruption of a Sirt1-dependent autophagy checkpoint in the prostate results in prostatic intraepithelial neoplasia lesion formation.Cancer Res. 2011;71:964-75.
178. Kung CP,Budina A,Balaburski G,Bergenstock MK,Murphy M.Autophagy in tumor suppression and cancer therapy.Crit Rev Eukaryot Gene Expr. 2011;21:71-100.
179. Imanishi S,Hayashi R,Ichikawa T,et al.SRT1720, a SIRT1 activator, aggravates bleomycin-induced lung injury in mice.Food Nutr Sci. 2012;3:157-63.